Achievement and safety of a low blood pressure goal in chronic renal disease: The Modification of Diet in Renal Disease Study group

Hypertension

Volumn 29, Issue 2, 1997, Pages 641-650

  Lazarus, J Michael ^a   Bourgoignie, Jacques J ^a   Buckalew, Vardaman M ^a   Greene, Tom ^a   Levey, Andrew S ^a   Milas, N Carole ^a   Paranandi, Lata ^a   Peterson, John C ^a   Porush, Jerome G ^a   Rauch, Sally ^a   Soucie, J Michael ^a   Stollar, Carol ^a   Beck, Gerald ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

blood pressure; drugs, antihypertensive; renal disease; safety

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; CORONARY RISK; DIET; FEMALE; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA;

EID: 0031028823     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.2.641     Document Type: Article

References (41)

1. Parving H-H, Anderson AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175-1179.
2. Bergström J, Alvestrand A, Bucht H, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol. 1986; 25:1-6.
3. Bauer JH, Reams GP, Lal SM. Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med. 1987;147: 1397-1400.
4. Brazy PC, Stead WW, Fitzwilliam J. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989;35:670-674.
5. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero C, Raij L. Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis. 1989;13:120-126.
6. Anderson S, Meyer T, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612-619.
7. Harris DCH, Hammond WS, Burke TJ, Schrier RW. Verapamil protects against progression of experimental chronic renal failure. Kidney Int. 1987;31:41-46.
8. Dworkin LD, Benstein JA. Impact of antihypertensive therapy on progressive kidney damage. Am J Hypertens. 1989;2:162S-172S.
9. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsch MJ. Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int. 1989;36:969-977.
10. Erley CM, Harrer U, Krämer K, Risler T. Renal hemodynamics and reduction of proteinuria by a vasodilating beta blocker versus an ACE inhibitor. Kidney Int. 1992;41:1297-1303.
11. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 1992;42:46-55.
12. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992; 42:452-458.
13. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD, Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;22:1456-1462.
14. Viberti GC, Mogensen CE, Groop LC, Pauls JF, European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994;271:275-279.
15. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J. 1992; 304:339-343.
16. Laffel LMB, McGill JB, Gans DJ, on behalf of the Northern American Microalbuminuria Study Group. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med. 1996;99:497-504.
17. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GS. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis. 1996;27:489-495.
18. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motelese M, Ponticelli C, Ritz E, Zucchelli P, and the Cooperative AIPRI Study Group. The effect of the angiotensin converting enzyme inhibitor benazepril on progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945.
19. Toto RD, Mitchell HC, Smith RD, Lee H-C, Mclntire D, Pettinger WA. 'Strict' blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995;48:851-859.
20. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker LG, Kusek JW, Striker GE, for the Modification of Diet in Renal Disease (MDRD) Study Group. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884.
21. Peterson JC, Adler SA, Burkart JM, Greene T, Hebert LA. Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123: 754-762.
22. Modification of Diet in Renal Disease Study Group (prepared by Kusek JW, Agodoa L, Greene T, Jones C). Comparison of decline of GFR in blacks vs non-blacks in the MDRD Study. J Am Soc Nephrol. 1993;4:253. Abstract.
23. Modification of Diet in Renal Disease (MDRD) Study Group (prepared by Beck GJ, Berg RL, Coggins CH, Gassman JJ, Hunsicker LG, Schluchter MD, Williams GW). Design and statistical issues of the Modification of Diet in Renal Disease Trial. Control Clin Trials. 1991;12:566-586.
24. Klahr S. The Modification of Diet in Renal Disease Study. N Engl J Med. 1989;320:864-866.
25. Yamamoto ME, Averbach FM, Caggiula AW, Jones FL, Gillis BP, and the Modification of Diet in Renal Disease (MDRD) Study. The production of quality dietary data: collaborative effort of the Modification of Diet in Renal Disease Study. J Renal Nutr. 1992;2: 117-125.
26. Modification of Diet in Renal Disease (MDRD) Study Group (prepared by Greene T, Bourgoignie JJ, Habwe V, Kusek JW, Snetselaar L, Soucie JM, Yamamoto M). Baseline characteristics in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1993;3: 1819-1834 (original version); 1993;4:1221-1236 (corrected version).
27. Modification of Diet in Renal Disease (MDRD) Study Group (prepared by Greene T, Bourgoignie JJ, Habwe V, Kusek JW, Snetselaar L, Soucie JM, Yamamoto M). Baseline characteristics in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1993;3: 1819-1834 (original version); 1993;4:1221-1236 (corrected version).
28. Modification of Diet in Renal Disease (MDRD) Study Group (prepared by Kusek JW, Coyne T, deVelasco A, Drabik MJ, Finlay RA, Gassman JJ, Kiefer S, Powers SN, Steinman TI). Recruitment experience in the full-scale phase of the Modification of Diet in Renal Disease Study. Control Clin Trials. 1993;14:538-557.
29. Frisancho AR. Instructions for Using the Frameter, Weight, Fat Guide and Anthropometrie Standards. Ann Arbor, Mich: Health Products; 1988:29-30.
30. Fifth Joint National Committee. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC-V). Arch Intern Med. 1993;153:154-183.
31. Joint National Committee. Report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1988;148:1023-1038.
32. Modification of Diet in Renal Disease (MDRD) Study Group (presented by Gassman JJ, Berg RL, Byington RP, Hebert LA, Lambdin KE, Tanna A). Selecting a point estimator of blood pressure from consecutive measurements. Control Clin Trials. 1991; 12:709-710.
33. US Department of Health and Human Services. The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Washington, DC: Public Health Service, Health Care Financing Administration; 1980. DHHS publication (PHS) 80-1260.
34. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
35. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman and Hall; 1984.
36. Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension. 1989;113:766-772.
37. Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in 'mild' hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med. 1982;307:976-980.
38. Samuelsson O, Wilhelmsen L, Andersson OK, Pennert K, Berglund G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. JAMA. 1987; 258:1768-1776.
39. Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M. INTERSALT study findings: public health and medical care implications. Hypertension. 1989;14:570-577.
40. Stamler R. Implications of the INTERSALT study. Hypertension. 1991;17(suppl I):I-16-I-20.
41. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stampler J. Blood pressure, stroke and coronary heart disease, part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.